
    
      In this multicenter, randomised controlled, phase 3 trial, patients with stage III-IVA
      (AJCC/UICC 8th system, except T3-4N0 and T3N1) non-metastatic nasopharyngeal carcinoma will
      be randomized in a 1:1 ratio to recieve PD-1 antibody for 12 doses every 3 weeks or best
      supportive care after curative chemoradiation.
    
  